Boston, MA -- (SBWIRE) -- 07/21/2012 -- GlobalData, the industry analysis specialist, has released its new report, "Acute Respiratory Distress Syndrome (ARDS) Therapeutics - Pipeline Assessment and Market Forecasts to 2019". The report is an essential source of information and analysis on the global Acute Respiratory Distress Syndrome (ARDS) Therapeutics market. The report identifies the key trends shaping and driving the global Acute Respiratory Distress Syndrome (ARDS) Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Acute Respiratory Distress Syndrome (ARDS) Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

View Full Report Details and Table of Contents

Scope

The report provides information on the key drivers and challenges of the Acute Respiratory Distress Syndrome (ARDS) Therapeutics market. Its scope includes -

- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Acute Respiratory Distress Syndrome (ARDS) Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Acute Respiratory Distress Syndrome (ARDS) Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Acute Respiratory Distress Syndrome (ARDS) Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Acute Respiratory Distress Syndrome (ARDS) Therapeutics market

Reasons to Get this Report

The report will enhance your decision making capability. It will allow you to -

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Acute Respiratory Distress Syndrome (ARDS) Therapeutics market.

Companies Mentioned in this Report: GlaxoSmithKline, Altor BioSciences, Faron Pharmaceuticals, Ltd., Mondobiotech

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- Acute Respiratory Distress Syndrome - Pipeline Review, H1 2012
- Acute Respiratory Distress Syndrome - Pipeline Review, H2 2011
- Acute Respiratory Distress Syndrome - Pipeline Review, Q1 2011
- Acute Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2019
- Cushing's Syndrome Therapeutics - Pipeline Assessment and Market Forecasts to 2019
- Sjogren's Syndrome Therapeutics - Pipeline Assessment and Market Forecasts to 2019
- Tourette Syndrome Therapeutics - Pipeline Assessment and Market Forecasts to 2019
- Hunter Syndrome Therapeutics - Pipeline Assessment and Market Forecasts to 2019
- Acute Respiratory Distress Syndrome Global Clinical Trials Review, H2, 2011
- Acute Upper Respiratory Infections (AURI) Therapeutics - Pipeline Assessment and Market Forecasts to 2017